Status:

RECRUITING

A Single-Arm Investigator-Initiated Tria (IIT) Evaluating the Safety and Preliminary Efficacy of Autologous Drug-Loaded Neutrophils (NeuMed) in Patients With Unresectable Pancreatic Cancer

Lead Sponsor:

The First Affiliated Hospital of Air Force Medicial University

Conditions:

Unresectable Pancreatic Cancer

Eligibility:

All Genders

18-70 years

Phase:

EARLY_PHASE1

Brief Summary

The goal of this clinical trial is to learn if Autologous Drug-Loaded Neutrophils (NeuMed) can treat patients with Unresectable Pancreatic Cancer. The drug carried by the Autologous Neutrophils is Mon...

Detailed Description

In this open, single-armed study, selected patients with Unresectable Pancreatic Cancer confirmed by Histopathology will be received Autologous Drug-Loaded Neutrophils (NeuMed)-based therapy. Neutroph...

Eligibility Criteria

Inclusion

  • 18-70 years
  • Obtain an informed consent form voluntarily signed by the patient themselves
  • patients with Unresectable Pancreatic Cancer confirmed by Histopathology
  • Patients who either: 1) have received standard first-line treatments, proven ineffective or causing intolerable adverse effects; or 2) have not received the standard first-line treatments and voluntarily opt for Autologous Drug-Loaded Neutrophils (NeuMed)-based therapy
  • EOCG score ≤ 2 and expected survival time ≥ 3 months
  • Liver, kidney and bone marrow functions are basically normal

Exclusion

  • Patients who required anti coagulant therapy
  • Patients with active infectious diseases or a history of bone marrow or organ transplantation
  • Patients with autoimmune diseases or autoinflammatory diseases
  • Patients with a history of severe cardiovascular or cerebrovascular diseases or interstitial lung disease or non-infectious pneumonia
  • Patients who have received live vaccines within 30 days prior to enrollment
  • Patients with no response to bone marrow mobilization
  • Other patients deemed unsuitable for enrollment by the investigator

Key Trial Info

Start Date :

July 14 2025

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

July 14 2027

Estimated Enrollment :

3 Patients enrolled

Trial Details

Trial ID

NCT07198659

Start Date

July 14 2025

End Date

July 14 2027

Last Update

September 30 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

The First Affiliated Hospital of the PLA Air Force Military Medical University

Xi’an, Shanxi, China, 710000